01—Abstract
Summary
Summary of the 10-K filed December 21, 2015. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported flat net revenue of $4.038 billiona for the fiscal year ended October 31, 2015, compared to the prior year.
This performance was significantly impacted by an unfavorable foreign currency movement of approximately 6 percentage points. The company experienced a decrease in revenue for its Life Sciences and Applied Markets segment due to softness in chemical and energy markets and a decline in the life sciences research market, partially offset by growth in the pharmaceutical and biotechnology sectors. The Diagnostics and Genomics segment revenue remained flat, despite strong demand in nucleic acid solutions and genomics, due to an unfavorable currency impact.
Agilent CrossLab, its consumables and services segment, saw a 2% revenue increase, driven by aftermarket services and consumables, though also affected by currency headwinds. Despite flat revenue, Agilent reported a significant increase in net income from continuing operations to $438 millionb in 2015, up from $232 million in 2014. This improvement was driven by higher gross margins, resulting from factors like favorable product mix and operational efficiencies, and reduced R&D and SG&A expenses (excluding certain items).
The company also completed the separation of its electronic measurement business, Keysight Technologies, Inc., on November 1, 2014. Agilent continued its capital return program by repurchasing shares and declaring dividends. However, the company disclosed a material weakness in internal controls over financial reporting related to the accounting for income taxes.
02—Key points
Key Highlights
- Net revenue remained flat at $4.038 billion for fiscal year 2015, impacted by a 6% unfavorable foreign currency movement.
- Net income from continuing operations significantly increased to $438 million in fiscal 2015, up from $232 million in fiscal 2014.
- The Life Sciences and Applied Markets segment experienced a 2% revenue decline, influenced by weaker chemical/energy markets and reduced life sciences research spending, though the pharmaceutical/biotech segments showed growth.
- The Diagnostics and Genomics segment reported flat revenue, with strong performance in nucleic acid solutions and genomics offset by currency impacts.
- Agilent CrossLab segment revenue grew 2%, driven by services and consumables, despite currency headwinds.
- Agilent completed the separation of its electronic measurement business (Keysight Technologies, Inc.) on November 1, 2014.
- The company reported a material weakness in internal controls over financial reporting related to accounting for income taxes.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2015, Agilent Technologies, Inc. kept $0.10.
- Revenue$4.04B100.0%
- Cost of revenue−$2.00B49.5%
- Gross profit$2.04B50.5%
- Operating costs−$1.52B37.6%
- Operating income$522.0M12.9%
- Interest, other & tax−$121.0M3.0%
- Net income$401.0M9.9%
Where FY2015 revenue went
$4.04B- Cost of revenue: $2.00B, 49% of revenue
- SG&A: $1.19B, 29% of revenue
- Net income: $401.0M, 9.9% of revenue
- R&D: $330.0M, 8.2% of revenue
- Interest, other & tax: $121.0M, 3.0% of revenue
Kept 9.9% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2015filed December 21, 2015Financial Statements
FY2015 against FY2014
| Line item | FY2015FY2014 | Change |
|---|---|---|
| Revenue | $4.04B$4.05B | −0.2% |
| Cost of Revenue | $2.00B$2.07B | −3.6% |
| Gross Profit | $2.04B$1.98B | +3.3% |
| R&D Expenses | $330.00M$358.00M | −7.8% |
| SG&A Expenses | $1.19B$1.20B | −0.8% |
| Operating Expenses | $3.52B$3.63B | −3.1% |
| Operating Income | $522.00M$419.00M | +24.6% |
| Interest Expense | $66.00M$110.00M | −40.0% |
| Net Income | $401.00M$549.00M | −27.0% |
| EPS (Basic) | $1.20$1.65 | −27.3% |
| EPS (Diluted) | $1.20$1.62 | −25.9% |
| Shares Outstanding (Basic) | 333.00M333.00M | 0.0% |
| Shares Outstanding (Diluted) | 335.00M338.00M | −0.9% |
05—Questions
Frequently Asked Questions
What was Agilent's overall financial performance in fiscal year 2015?
Agilent Technologies reported flat net revenue of $4.038 billion for the fiscal year ended October 31, 2015. Despite flat revenue, net income from continuing operations saw a significant increase to $438 million from $232 million in the prior year, driven by improved gross margins and cost management.
How did the separation of Keysight Technologies affect Agilent?
Agilent completed the separation of its electronic measurement business, Keysight Technologies, Inc., on November 1, 2014, by distributing 100% of Keysight's common shares to Agilent stockholders. The historical results of Keysight were reported as discontinued operations in Agilent's financial statements until the separation.
What are the key business segments of Agilent, and how did they perform?
Agilent operates in three segments: Life Sciences and Applied Markets (revenue decreased 2%), Diagnostics and Genomics (revenue was flat), and Agilent CrossLab (revenue increased 2%). The Life Sciences and Applied Markets segment was impacted by weaker chemical/energy markets, while Diagnostics and Genomics faced currency headwinds. Agilent CrossLab saw growth from services and consumables.
Did Agilent return capital to shareholders in fiscal year 2015?
Yes, Agilent continued its capital return strategy by repurchasing approximately 6 million shares for $267 million and declared quarterly dividends totaling $0.40 per share for the fiscal year.
Are there any significant internal control issues disclosed?
Yes, Agilent disclosed a material weakness in its internal control over financial reporting related to the accounting for income taxes. Management is working on enhancements to address this issue, expecting remediation in fiscal year 2016.
06—Continue